{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T03:38:28Z","timestamp":1764905908347,"version":"3.44.0"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jneuroim.2020.577267","type":"journal-article","created":{"date-parts":[[2020,5,21]],"date-time":"2020-05-21T11:39:57Z","timestamp":1590061197000},"page":"577267","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Guillain-Barr\u00e9 Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming"],"prefix":"10.1016","volume":"346","author":[{"given":"Catherine","family":"Maurice","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Khoja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Morgan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Warren P.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans","family":"Katzberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Austin M.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcus","family":"Butler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jneuroim.2020.577267_bb0005","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577267_bb0010","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1158\/2326-6066.CIR-13-0092","article-title":"Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy","volume":"1","author":"Johnson","year":"2013","journal-title":"Cancer Immunol. Res."},{"issue":"6","key":"10.1016\/j.jneuroim.2020.577267_bb0015","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1634\/theoncologist.2012-0391","article-title":"Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma","volume":"18","author":"Luke","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.jneuroim.2020.577267_bb0020","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/S1470-2045(14)70012-9","article-title":"Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study","volume":"15","author":"McArthur","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.jneuroim.2020.577267_bb0025","series-title":"Presented at the European Cancer Congress (ECCO-ESMO-ESTRO), Amsterdam, Netherlands, September 27\u2013October 1","article-title":"Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in metastatic or locally advanced, unresectable melanoma","author":"Schadendorf","year":"2013"},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577267_bb0030","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/annonc\/mdt587","article-title":"Differential influence of vemurefenib and dabrafenib on patient\u2019s lymphocytes despite similar clinical efficacy in melanoma","volume":"25","author":"Schilling","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.jneuroim.2020.577267_bb0035","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1084\/jem.20051848","article-title":"The BRAF\u2013MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells","volume":"203","author":"Sumimoto","year":"2006","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.jneuroim.2020.577267_bb0040","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820300291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820300291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:36:32Z","timestamp":1759048592000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820300291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":8,"alternative-id":["S0165572820300291"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577267","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guillain-Barr\u00e9 Syndrome following a series of novel therapies adapting the gold-standard in the era of immune priming","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577267","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"577267"}}